Hints and tips:
Refine results
Sandoz worked with NHS on ‘copycat’ drug despite risk of no quick commercial return
Choking off copycat drugs is a bad strategy
Company says test results show ‘unambiguous’ improvement in survival rates
FT 1000 Asia-Pacific list shows sector is another friendly rivalry to span the Tasman Sea
Merck slides and Incyte loses $4bn market value as ‘combination’ cancer study flops
Doubts hang over acquisitions struck when the industry was in the grip of an M&A frenzy
Clinical setbacks in cancer research are likely to be punished
Takeda considers Shire bid, Waymo and JLR pair up, Carlyle and Remington’s last shot
Swiss group focuses on pharma as $13bn deal hands UK partner control of consumer unit
Move to shed consumer health unit by Swiss group’s new CEO aims at focusing business
Failure to sell its consumer healthcare unit has left pharma group looking for a cure
Pharma group’s decision not to bid for consumer healthcare unit puts sale in doubt
UK drugmaker slides on news rival opioid addiction treatment does not infringe patents
A deal could give significant lift to earnings after three years
Shareholders have lost faith after biotech titan failed to give substance to hype
Reckitt’s decision to abandon potential $20bn deal cheered by some but rued by others
Pharma group’s shares fall by 11 per cent after lung cancer drug setback
Drugmaker tops Reckitt Benckiser bid for consumer health business
Flu victim should have paid much less for her medication, data show
Rival Reckitt Benckiser falls back in the bidding for Advil maker
Clear all selected filters
